FY2025 · ended Dec 31, 2025 · Revenue $16.10M, +50.7% YoY · Filed Mar 5, 2026
Profound Medical Corp. (PROF) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $16.1 million and a net loss of $42.6 million. Free cash flow was -$38.4 million. As of Jun 30, 2026 it held $38.3 million in cash and investments and $11.9 million in total debt.
Revenue (TTM)
$19.09M
Net income (TTM)
$-32.74M
Operating cash flow (TTM)
$-36.10M
Free cash flow
$-38.38M
-71.4% vs prior year
EPS (TTM)
$1.57
Dividend per share
None
Shares outstanding
36.29M
+20.8% vs prior year
Net cash
$26.39M
as of Jun 30, 2026
Operating margin
-185.3%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- PROF (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Ontario, Canada
- Headquarters
- Mississauga, Ontario, Canada
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1628808
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $16.1M | $10.7M | $5.9M | $6.0M | $6.4M |
| Operating income | -$41.3M | -$33.1M | — | — | — |
| Net income | -$42.6M | -$27.8M | — | — | — |
| Diluted EPS | $1.41 | $1.12 | — | — | — |
| Operating cash flow | -$38.2M | -$23.5M | -$22.3M | -$25.8M | -$22.4M |
| Free cash flow | -$38.4M | — | — | — | -$22.4M |
| Total assets | $77.5M | $70.2M | $44.0M | $64.4M | $86.8M |
| Total liabilities | $11.0M | $9.8M | $12.7M | $12.4M | $6.2M |
| Stockholders' equity | $66.4M | $60.4M | — | — | — |
| Cash and investments | $59.7M | $54.9M | $26.2M | $46.5M | $67.2M |
| Total debt | $4.7M | $5.1M | $7.9M | $8.2M | $1.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Nov 3, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 22, 2026 | Oct 22, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 14, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 9, 2026 | Oct 9, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 7, 2026 | Oct 7, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 4, 2026 | Sep 3, 2026 |
All 286 Profound Medical Corp. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.